Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals, Inc. (RIGL) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · RIGL · as of Jun 8, 2026
Activity summary
Buy transactions
0
P-Purchase only
Sell transactions
2
12 Months
Buy/Sell ratio
0.00
Buy/Sell (by trades)
Overall sentiment
Rigel Pharmaceuticals, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 8, 2026
RIGL insider buying and selling by quarter
RIGL insider selling · RIGL insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 8, 2026
Active insiders
Most active in past 12 months · RIGL ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
RIGL executive sell shares · RIGL board member insider trading · RIGL insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Jun 1, 2026 | Schorno Dean L EVP & Chief Financial Officer | Option | 2,181 | $28K | Form 4 |
| Jun 1, 2026 | Schorno Dean L EVP & Chief Financial Officer | Other | 928 | $28K | Form 4 |
| Jun 1, 2026 | Schorno Dean L EVP & Chief Financial Officer | Option | 1,200 | $22K | Form 4 |
| Jun 1, 2026 | Santos David A EVP, Chief Commercial Officer | Other | 874 | $26K | Form 4 |
| Jun 1, 2026 | Rojkjaer Lisa EVP, Chief Medical Officer | Other | 850 | $25K | Form 4 |
| Jun 1, 2026 | RODRIGUEZ RAUL R CEO, President · Director | Other | 2,424 | $72K | Form 4 |
| Jun 1, 2026 | Furey Raymond J. EVP, GC, CCO & Corp Sec | Other | 877 | $26K | Form 4 |
| May 26, 2026 | Ali-Jackson Kamil Director | Sale | 2,500 | $73K | Form 4 |
| May 15, 2026 | Wasman Jane Director | Award | 5,750 | — | Form 4 |
| May 15, 2026 | MOOS WALTER H Director | Award | 5,750 | — | Form 4 |
| May 15, 2026 | MILLER MICHAEL PATRICK Director | Award | 5,750 | — | Form 4 |
| May 15, 2026 | LAPOINTE ANTHONY GREGG Director | Award | 5,750 | — | Form 4 |
| May 15, 2026 | HANNAH ALISON L. Director | Award | 5,750 | — | Form 4 |
| May 15, 2026 | Frohlich Mark W Director | Award | 5,750 | — | Form 4 |
| May 15, 2026 | Ali-Jackson Kamil Director | Award | 5,750 | — | Form 4 |
| Feb 20, 2026 | MOOS WALTER H Director | Option | 4,000 | $96K | Form 4 |
| Feb 20, 2026 | MOOS WALTER H Director | Sale | 4,000 | $145K | Form 4 |
| Feb 17, 2026 | Furey Raymond J. EVP, GC, CCO & Corp Sec | Award | 19,497 | — | Form 4 |
| Feb 17, 2026 | RODRIGUEZ RAUL R CEO, President · Director | Award | 53,915 | — | Form 4 |
| Feb 17, 2026 | Rojkjaer Lisa EVP, Chief Medical Officer | Award | 18,894 | — | Form 4 |
| Feb 17, 2026 | Schorno Dean L EVP & Chief Financial Officer | Award | 20,636 | — | Form 4 |
| Feb 17, 2026 | Santos David A EVP, Chief Commercial Officer | Award | 19,430 | — | Form 4 |
| Feb 10, 2026 | Schorno Dean L EVP & Chief Financial Officer | Other | 3,546 | $123K | Form 4 |
| Feb 10, 2026 | Furey Raymond J. EVP, GC, CCO & Corp Sec | Other | 3,546 | $123K | Form 4 |
| Feb 10, 2026 | Santos David A EVP, Chief Commercial Officer | Other | 3,546 | $123K | Form 4 |
Schorno Dean L
EVP & Chief Financial Officer
Date
Jun 1
Shares
2,181
Price
$12.70
Value
$28K
Schorno Dean L
EVP & Chief Financial Officer
Date
Jun 1
Shares
928
Price
$29.86
Value
$28K
Schorno Dean L
EVP & Chief Financial Officer
Date
Jun 1
Shares
1,200
Price
$18.70
Value
$22K
Santos David A
EVP, Chief Commercial Officer
Date
Jun 1
Shares
874
Price
$29.86
Value
$26K
Rojkjaer Lisa
EVP, Chief Medical Officer
Date
Jun 1
Shares
850
Price
$29.86
Value
$25K
RODRIGUEZ RAUL R
CEO, President · Director
Date
Jun 1
Shares
2,424
Price
$29.86
Value
$72K
Furey Raymond J.
EVP, GC, CCO & Corp Sec
Date
Jun 1
Shares
877
Price
$29.86
Value
$26K
Furey Raymond J.
EVP, GC, CCO & Corp Sec
Date
Feb 17
Shares
19,497
Price
—
Value
—
RODRIGUEZ RAUL R
CEO, President · Director
Date
Feb 17
Shares
53,915
Price
—
Value
—
Rojkjaer Lisa
EVP, Chief Medical Officer
Date
Feb 17
Shares
18,894
Price
—
Value
—
Schorno Dean L
EVP & Chief Financial Officer
Date
Feb 17
Shares
20,636
Price
—
Value
—
Santos David A
EVP, Chief Commercial Officer
Date
Feb 17
Shares
19,430
Price
—
Value
—
Schorno Dean L
EVP & Chief Financial Officer
Date
Feb 10
Shares
3,546
Price
$34.62
Value
$123K
Furey Raymond J.
EVP, GC, CCO & Corp Sec
Date
Feb 10
Shares
3,546
Price
$34.62
Value
$123K
Santos David A
EVP, Chief Commercial Officer
Date
Feb 10
Shares
3,546
Price
$34.62
Value
$123K
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About RIGL insider trading
RIGL insider trades
Rigel Pharmaceuticals, Inc. (RIGL) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Schorno Dean L (EVP & Chief Financial Officer), RODRIGUEZ RAUL R (CEO, President · Director), Santos David A (EVP, Chief Commercial Officer). Over the past 12 months, 5 insiders have filed transactions with the SEC. RIGL insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Rigel Pharmaceuticals, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
RIGL insider trading · 5 questionsThe insiders of Rigel Pharmaceuticals, Inc. (RIGL) include executives and directors such as Schorno Dean L (EVP & Chief Financial Officer), RODRIGUEZ RAUL R (CEO, President · Director), Santos David A (EVP, Chief Commercial Officer), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026